Physician profile
Peter A Koretsky
NPI 1467556456
$4,511.14
in general payments reported to CMS, 2019-2025
25 companies · $834 in 2025
The $834 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $121 · 2021: $319 · 2022: $653 · 2023: $838 · 2024: $940 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,612.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,515.01 | 2019-2025 | |
| Janssen Biotech, INC. | $553.30 | 2022-2025 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $388.47 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $272.47 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.93 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $193.74 | 2019-2025 | Entyvio, Eohilia, Gattex |
| E.R. Squibb & Sons, L.L.C. | $191.99 | 2021-2022 | |
| Genzyme Corporation | $144.86 | 2022-2025 | |
| Gilead Sciences, INC. | $124.86 | 2019-2025 | |
| Pfizer INC. | $119.47 | 2019 | |
| Intercept Pharmaceuticals, INC. | $90.02 | 2019-2024 | Ocaliva |
| Medtronic, INC. | $86.85 | 2021-2024 | Interstim |
| Novo Nordisk INC | $74.62 | 2025 | Wegovy, Ozempic |
| Lucid Diagnostics INC. | $64.98 | 2024 | |
| Ferring Pharmaceuticals INC. | $64.32 | 2019-2024 | Rebyota |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $59.22 | 2019 | |
| Braintree Laboratories, INC. | $55.52 | 2019-2024 | Suflave, Sutab |
| Nestle Healthcare Nutrition INC. | $51.98 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.71 | 2023-2024 | Cyltezo |
| Regeneron Healthcare Solutions, INC. | $44.42 | 2023 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $31.08 | 2025 | Iqirvo |
| Shire North American Group INC | $30.39 | 2019 | |
| Enterra Medical, INC. | $19.85 | 2024 | |
| Axonics, INC. | $16.82 | 2024 | Axonics |
| Ironwood Pharmaceuticals, INC | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Koretsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.